Source: International Congress 2017 – The latest in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Jair Bar (Tel Aviv, Israel). Immunotherapy in locally advanced and metastasized NSCLC: 2nd line, 1st line, liftoff!. International Congress 2017 – The latest in lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer? Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? Source: ERJ Open Res, 6 (1) 00159-2019; 10.1183/23120541.00159-2019 Year: 2020 Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight Source: ERS webinar 2021: Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight Year: 2021 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the (pneumo) oncologist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007 A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Management of locally advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 260–270 Year: 2009 Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed (Pem) for advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the radiotherapist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Relapsed NSCLC and SCLC: benefits and limitations of systemic treatments beyond the second line Source: International Congress 2017 – Rational strategies for specific treatment situations in lung cancer Year: 2017 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 The comparison of paclitaxel-carboplatin (PCp) versus gemcitabine-cisplatin (GC) in the treatment of locally advanced or metastatic non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Procalcitonin serum levels in patients with stage IV non-small cell lung cancer in first line of chemotherapy Source: International Congress 2016 – Clinical aspects of lung cancer Year: 2016 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005